



VIA HAND DELIVERY JULY 2001

RECH CENTER 1600/2900

JUL 31 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Moore et al.

Attorney Docket No.: PF466P1

Application Serial No.: 09/376,430

Art Unit: 1646

Filed: August 18, 1999

Examiner: O'Hara, E.

Title: **Cytokine Receptor Common
Gamma Chain Like**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the reference AH listed on the attached Form PTO/SB/08A.

A copy of reference AH was cited by the Examiner in connection with United States Patent Application Serial No. 09/263,626, filed March 5, 1999, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 09/263,626 for a copy of reference AH.

The listed reference is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner review the listed reference and that the reference be made of record in the file history of the application.

Identification of the listed reference is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such reference is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over the

RECEIVED
JUL 31 2001
RECH CENTER 1600/2900

listed document should it be applied as a reference against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(e)(2), the undersigned certifies that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this information disclosure statement.

The Commissioner is hereby authorized to charge Deposit Account No. 08-3425 in the amount of \$180.00 as payment of the fee required under 37 C.F.R. § 1.17(p).

Respectfully submitted,

Dated: July 26, 2001


Janet M. Martineau (Reg. No. 46,903)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 315-2723

MMW/JMM/CB/ba
Enclosures